Kit for detecting drug sensitivity of rectal cancer cells based on gene mutation analysis

A technology of drug sensitivity and gene variation, applied in the field of disease detection, can solve the problems of poor drug efficacy, cumbersome, individual differences, etc., and achieve highly targeted effects

Active Publication Date: 2019-09-03
THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that after treatment, when there is more wild-type P53 gene protein in rectal cancer patients, it indicates that the drug has better efficacy. On the contrary, if there is more mutant P53 gene protein, it indicates that the drug has poor efficacy.
The traditional detection methods used in the prior art are too cumbersome, which is not conducive ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for detecting drug sensitivity of rectal cancer cells based on gene mutation analysis
  • Kit for detecting drug sensitivity of rectal cancer cells based on gene mutation analysis
  • Kit for detecting drug sensitivity of rectal cancer cells based on gene mutation analysis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] A kit for detecting drug sensitivity of colorectal cancer cells based on gene variation analysis, consisting of the following substances:

[0041] (1) An injection containing 20% ​​rectal cancer cell drug (TAS 102) by mass fraction;

[0042] (2) Contain magnetic nanoparticle indicator solution A that is surface-modified by green fluorescent protein-labeled wild P53 protein antibody; preparing magnetic nanoparticle indicator solution A includes the following steps:

[0043] A1: Surface activation of magnetic nanoparticles with glutaraldehyde;

[0044] A2: Add the activated magnetic nanoparticles to the wild P53 protein antibody solution with a mass ratio of 1.4 times, and ultrasonically load for 1.5 hours;

[0045] A3: Add green fluorescent protein solution equal to the volume of the wild P53 protein antibody solution, and 7 μg / mL EDC, and react for 2.5 hours at pH 7.2 and temperature 6°C to obtain green fluorescent protein-labeled wild Suspension I of magnetic nanopar...

Embodiment 2

[0066] This embodiment is basically the same as Embodiment 1, and the difference points out that:

[0067] The colorectal cancer cell drug is loaded on a slow-release carrier. The sustained-release carrier can be polylactic acid microspheres, which are embedded and loaded by spray-drying method, and are used for the release of controlled-release drugs, so as to prevent the drugs from being consumed too quickly, thereby affecting the accuracy of drug efficacy testing.

Embodiment 3

[0069] This embodiment is basically the same as Embodiment 2, and the difference points out that:

[0070] The colorectal cancer cell drug is Regorafenib.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a kit for detecting drug sensitivity of rectal cancer cells based on gene mutation analysis, which comprises the following substances: (1) a rectal cancer cell drug reagent, (2) a magnetic nanoparticle indicating liquid A with a green fluorescent protein labeling a wild P53 protein antibody for surface modification, (3) a magnetic nanoparticle indicating liquid B with a redfluorescent protein labeling an anti-mutation P53 protein antibody for surface modification and (4) a substrate medium and a dilution buffer. The sensitivity of a patient to the drug is measured through simultaneous calculation of the expression levels of the wild P53 gene protein and the mutant P53 gene protein, the individualization is more prominent, the detection result is more accurate, a sensitive drug is screened for the treatment of the disease, and an optimal chemotherapy regimen is selected.

Description

technical field [0001] The invention relates to the technical field of disease detection, in particular to a kit for detecting drug sensitivity of rectal cancer cells based on gene variation analysis and a detection method thereof. Background technique [0002] Rectal cancer refers to cancer between the dentate line and the rectosigmoid junction, and is one of the most common malignant tumors of the digestive tract. Since tumor is a special cell population, the sensitivity to the same drug is also different, so the effect of tumor chemotherapy in different patients is also different. Improper chemotherapy can neither alleviate the condition, but also bring great toxic and side effects to patients, which leads to treatment failure. Therefore, in actual operation, individualized treatment plans are selected according to various clinical and pathological data of patients, such as tumor type, stage, and previous treatment history, combined with drug sensitivity test results, so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574G01N33/543G01N33/533
CPCG01N33/57446G01N33/54326G01N33/54346G01N33/533
Inventor 章俊高婷李珀
Owner THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products